Published in final edited form as:

Perfusion. 2014 January ; 29(1): 53–56. doi:10.1177/0267659113498807.

Venoarterial extracorporeal membrane oxygenation for the management of massive amlodipine overdose

RL Weinberg¹, NC Bouchard², DC Abrams³, M Bacchetta⁴, AL Dzierba⁵, KM Burkart³, and D Brodie³

¹Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, Division of Cardiology, Department of Medicine, New York, NY, USA

²Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, Departments of Emergency Medicine and Medical Toxicology, New York, NY, USA

³Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, Division of Pulmonary, Allergy and Critical Care, Department of Medicine, New York, NY, USA

⁴Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, Division of Thoracic Surgery, Department of Surgery, New York, NY, USA

⁵Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, Department of Pharmacy, New York, NY, USA

Abstract

A 50-year-old man was admitted to the intensive care unit with respiratory failure and shock after suffering a massive overdose of amlodipine, lisinopril and hydrochlorothiazide. Despite mechanical ventilation, vasopressors, calcium gluconate, hyperinsulinemia-euglycemia therapy, methylene blue and intravenous fat emulsion, the patient's respiratory and hemodynamic status deteriorated. Venoarterial extracorporeal membrane oxygenation (ECMO) was initiated to provide cardiopulmonary support in the setting of profound respiratory failure and refractory shock. The patient was placed on ECMO 19 hours after arrival to the hospital, after which vasopressor and ventilatory requirements decreased significantly. The patient was decannulated from ECMO after 8 days and was discharged home after a 56-day hospitalization. Early institution of ECMO should be considered for the management of respiratory failure and refractory shock in the setting of calcium channel blocker overdose when medical therapies are insufficient.

Keywords

ECMO; amlodipine; overdose; shock; respiratory failure

© The Author(s) 2013

Reprints and permissions: sagepub.co.uk/journalsPermissions.nav

Corresponding author: Daniel Brodie, Columbia University College of Physicians and Surgeons, Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, 622 W. 168th St, PH 8E 101, New York, NY 10032. hdb5@columbia.edu.

Introduction

Calcium channel blockers (CCBs) accounted for 34% of cardiovascular drug-related deaths and 3.2% of all deaths due to pharmaceutical exposures reported to poison control centers in 2011.¹ Amlodipine is often favored over other CCBs due to its selectivity for peripheral vasculature and once-daily dosing. However, with a half-life of approximately 34 hours and a loss of vascular selectivity at high doses, the management of amlodipine overdose is challenging.² We describe the successful use of venoarterial extracorporeal membrane oxygenation (ECMO) for severe hypoxemic respiratory failure and refractory shock due to amlodipine overdose after the failure of conventional medical management.

Case History

A 50-year-old man with a history of depression and alcohol abuse was brought to the hospital after the ingestion of 500 mg of amlodipine, 1000 mg of lisinopril, and 625 mg of hydrochlorothiazide, in a suicide attempt. Upon arrival, the patient was normotensive and tachycardic, with normal oxygen saturation. Neurologic status was intact and an electrocardiogram showed normal conduction. Within 1 hour, the patient developed hypotension to a blood pressure nadir of 50/34 mmHg and became obtunded. He was intubated, started on dopamine, norepinephrine, normal saline, calcium gluconate and glucagon and was transferred to the intensive care unit (ICU). Given the concern that amlodipine toxicity was the etiology of his shock, hyperinsulinemia-euglycemia therapy was initiated with insulin. After fluid resuscitation, the central venous pressure was 22 mmHg; however, he remained in shock. Phenylephrine, vasopressin and epinephrine were added and maximized without hemodynamic improvement (Figure 1). Severe hypoxemic respiratory failure developed, with a ratio of the partial pressure of oxygen in arterial blood (PaO_2) to the fraction of inspired oxygen (FiO_2) of 79. A transthoracic echocardiogram revealed a left ventricular ejection fraction of 70%. Laboratory analysis demonstrated severe hypokalemia, hypophosphatemia and renal failure.

In the setting of severe hypoxemia and ongoing shock, with blood pressures ranging from 69/39 to 92/31 mmHg despite maximal therapy, including the addition of methylene blue and intravenous fat emulsion, he was started on venoarterial ECMO. The circuit consisted of a Rotaflow centrifugal pump (Maquet Cardiovascular, Hirrlingen, Germany), a Quadrox D oxygenator (Maquet), a 24 Fr elongated one-piece arterial cannula (Medtronic, Minneapolis, MN) grafted to the right axillary artery and a 24 Fr multi-port venous cannula (Avalon Laboratories, LLC, Rancho Dominguez, CA) in the left femoral vein.³ The blood flow rate was 5.6 L/min, the sweep gas flow rate was 3.0 L/min and the fraction of delivered oxygen was 1.0. Heparin was administered for anticoagulation, with a goal activated partial thrombo-plastin time of 40 to 60 seconds. The FiO_2 on the ventilator was reduced to 0.4 with a PaO_2 of 212 mmHg.

Transthoracic echocardiogram on ECMO day 2 showed a newly reduced left ventricular ejection fraction of 10%. Despite the reduced cardiac function, vasopressors and inotropes were successfully weaned in the setting of ongoing venoarterial extracorporeal support. He was decannulated from ECMO after 8 days and remained hemodynamically stable. On ICU

day 17 he was liberated from mechanical ventilation without the need for supplemental oxygen.

The ICU course was notable for renal failure that required temporary continuous venovenous hemodialysis, *S. epidermidis* bacteremia, and drainage of a loculated pericardial effusion. Left ventricular function improved to 45% during his hospitalization. He was discharged from the hospital with an intact mental status on hospital day 56 and returned to functional independence.

Discussion

CCB overdose may cause significant morbidity and mortality.¹ Although dihydropyridine CCBs generally have been thought to be less lethal in overdose due to their selectivity for the peripheral vasculature and lesser effect on the conduction system, they have been documented to cause profound hypotension, bradyarrhythmias and shock.^{4,5} Amlodipine is extensively protein bound with a large volume of distribution and, therefore, not dialyzable. Thus, the treatment of CCB overdose focuses on overcoming its effects on vascular smooth muscle, cardiac myocytes and conduction tissue, and pancreatic beta cells.⁴⁻⁶ The combination of dihydropyridine CCBs and angiotensin converting enzyme inhibitors or angiotensin receptor blockers may blunt vasoconstrictive and sympathetic responses and worsen CCB toxicity.⁷ The ingestion of an excessive dose of lisinopril, in addition to the overdose of amlodipine, may help to explain the refractory nature of this patient's vasodilatory shock. The etiology of the patient's hypoxemic respiratory failure could not be definitively elucidated in this case, though non-cardiogenic pulmonary edema has been described as a complication of CCB overdose and may explain our patient's hypoxemia.^{1,8-10} Invasive mechanical ventilation is usually sufficient to manage such sequelae. The use of ECMO has been reported for the management of overdose-related respiratory failure that has failed conventional management, though not specifically in the setting of CCBs.¹¹⁻¹³ This case report illustrates the use of ECMO for both mechanical circulatory and respiratory support when medical therapy alone was insufficient.

The patient was volume resuscitated and a calcium infusion was started in an attempt to overcome calcium channel antagonism, despite which he required adrenergic agonists and vasopressors for hypotension. Case reports indicate that adrenergic agents have had some success in treating CCB overdose;^{4,5,7} however, our patient remained in refractory vasodilatory shock. Glucagon was administered in an attempt to activate adenylate cyclase independent of beta adrenergic receptors, but was unsuccessful.¹⁴ Other medical therapies were attempted, including hyperinsulinemia-euglycemia therapy, methylene blue and intravenous fat emulsion. Insulin's property as a positive inotrope and its ability to improve carbohydrate metabolism may provide a benefit in CCB overdose.^{15,16} Methylene blue, by scavenging nitric oxide, may have a role in refractory septic shock, cardiopulmonary bypass-induced vasodilation and anaphylaxis; however, it had no effect in our patient.¹⁷⁻²⁰ Emulsion infusion, which creates an expanded lipid phase in the blood that leads to a redistribution and trapping of tissue-bound drug, has been used in medication overdoses, but did not have any benefit here.²¹⁻²³ Given his rapidly deteriorating oxygenation and refractory shock, the decision was made to initiate venoarterial ECMO. The infusion of

intravenous fat emulsion in patients on ECMO has been reported to cause agglutination in the ECMO circuit, though none was noted in this case.²⁴

There is a growing body of literature on extracorporeal support for refractory shock or cardiotoxicity due to poisoning.^{13,25-29} Our use of venoarterial ECMO was prompted by severe hypoxemia superimposed on refractory vasodilatory shock. A venoarterial configuration proved additionally helpful when the patient developed a severe cardiomyopathy. The use of an arterial reinfusion cannula grafted to an axillary artery, as opposed to a femoral artery, provided the added benefit of delivering oxygenated blood more directly to the aortic arch, maximizing oxygen delivery to the coronary and cerebral vascular beds.³ During the eight days of ECMO support, there were no alterations to the configuration, replacement of circuit components or complications related to the circuit. Given the patient's potentially reversible cause of shock and respiratory failure, the goal of ECMO was to provide temporary respiratory and hemodynamic support until his body was able to metabolize the amlodipine, lisinopril and hydrochlorothiazide.

Conclusion

ECMO may be considered in cases of hypoxemic respiratory failure and refractory shock in the setting of CCB overdose when medical therapy is ineffective.

Acknowledgments

We would like to thank Drs. Keith Brenner, Monica Goldklang, and Hiroo Takayama at Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, and Drs. Robert Hoffman and Zhanna Livshits at the New York City Poison Control Center for their invaluable contributions to the care of this patient.

Declaration of conflicting interest: Dr. Brodie reports receiving research support from Maquet Cardiovascular, including travel expenses for research meetings, research support for the present study as well as anticipated support for upcoming studies and compensation paid to Columbia University for research consulting. He receives no direct compensation from Maquet. Dr. Brodie is a member of the Medical Advisory Board for ALung Technologies. Compensation is paid to Columbia University. Dr. Brodie receives no direct compensation from ALung Technologies. Dr. Matthew Bacchetta reports receiving research support from Maquet Cardiovascular, including travel expenses for research meetings, research support for the present study as well as anticipated support for upcoming studies. He receives no direct compensation from Maquet.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

References

1. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. *Clin Toxicol (Phila)*. 2012; 50:911–1164. [PubMed: 23272763]
2. Abernethy DR. The pharmacokinetic profile of amlodipine. *Am Heart J*. 1989; 118:1100–1103. [PubMed: 2530866]
3. Javidfar J, Brodie D, Costa J, et al. Subclavian artery cannulation for venoarterial extracorporeal membrane oxygenation. *ASAIO J*. 2012; 58:494–498. [PubMed: 22929897]
4. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. *Toxicol Rev*. 2004; 23:223–238. [PubMed: 15898828]
5. Harris NS. Case records of the Massachusetts General Hospital. Case 24–2006. A 40-year-old woman with hypotension after an overdose of amlodipine. *N Engl J Med*. 2006; 355:602–611. [PubMed: 16899781]

6. Brunton, LL.; Lazo, JS.; Parker, KLP. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th. New York: McGraw - Hill; 2005.
7. Smith SW, Ferguson KL, Hoffman RS, Nelson LS, Greller HA. Prolonged severe hypotension following combined amlodipine and valsartan ingestion. Clin Toxicol (Phila). 2008; 46:470–474. [PubMed: 18568804]
8. Siddiqi TA, Hill J, Huckleberry Y, Parthasarathy S. Non-cardiogenic pulmonary edema and life-threatening shock due to calcium channel blocker overdose and its management: a case report and a clinical review. Respir Care. 2013 Epub ahead of print.
9. Kute VB, Shah PR, Gopani KR, Gumber MR, Vanikar AV, Trivedi HL. Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine. Indian J Crit Care Med. 2011; 15:182–184. [PubMed: 22013313]
10. Humbert VH Jr, Munn NJ, Hawkins RF. Noncardiogenic pulmonary edema complicating massive diltiazem overdose. Chest. 1991; 99:258–259. [PubMed: 1984972]
11. Pizon AF, Brooks DE. Fentanyl patch abuse: naloxone complications and extracorporeal membrane oxygenation rescue. Vet Hum Toxicol. 2004; 46:256–257. [PubMed: 15487648]
12. Ishigami S, Hase S, Nakashima H, et al. Intravenous chlorhexidine gluconate causing acute respiratory distress syndrome. J Toxicol Clin Toxicol. 2001; 39:77–80. [PubMed: 11327231]
13. Baud FJ, Megarbane B, Deye N, Leprince P. Clinical review: aggressive management and extracorporeal support for drug-induced cardiotoxicity. Crit Care. 2007; 11:207. [PubMed: 17367544]
14. Walter FG, Frye G, Mullen JT, Ekins BR, Khasigian PA. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med. 1993; 22:1234–1237. [PubMed: 8517581]
15. Yuan TH, Kerns WP 2nd, Tomaszewski CA, Ford MD, Kline JA. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999; 37:463–474. [PubMed: 10465243]
16. Boyer EW, Shannon M. Treatment of calcium-channel-blocker intoxication with insulin infusion. N Engl J Med. 2001; 344:1721–1722. [PubMed: 11386285]
17. Del Duca D, Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg. 2009; 87:640–642. [PubMed: 19161806]
18. Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med. 2006; 21:359–363. [PubMed: 17095500]
19. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004; 77:496–499. [PubMed: 14759425]
20. Shanmugam G. Vasoplegic syndrome--the role of methylene blue. Eur J Cardiothorac Surg. 2005; 28:705–710. [PubMed: 16143539]
21. Engels PT, Davidow JS. Intravenous fat emulsion to reverse haemodynamic instability from intentional ami-triptyline overdose. Resuscitation. 2010; 81:1037–1039. [PubMed: 20605670]
22. Freedberg RS, Friedman GR, Palu RN, Feit F. Cardiogenic shock due to antihistamine overdose. Reversal with intraaortic balloon counterpulsation. JAMA. 1987; 257:660–661. [PubMed: 3098994]
23. Turner-Lawrence DE, Kerns Li W. Intravenous fat emulsion: a potential novel antidote. J Med Toxicol. 2008; 4:109–114. [PubMed: 18570172]
24. Buck ML, Wooldridge P, Ksenich RA. Comparison of methods for intravenous infusion of fat emulsion during extracorporeal membrane oxygenation. Pharmacotherapy. 2005; 25:1536–1540. [PubMed: 16232016]
25. Daubin C, Lehoux P, Ivascau C, et al. Extracorporeal life support in severe drug intoxication: a retrospective cohort study of seventeen cases. Crit Care. 2009; 13:R138. [PubMed: 19706166]
26. Purkayastha S, Bhangoo P, Athanasiou T, et al. Treatment of poisoning induced cardiac impairment using cardiopulmonary bypass: a review. Emerg Med J. 2006; 23:246–250. [PubMed: 16549566]
27. Pasic M, Hetzer R. Cardiopulmonary bypass and severe drug intoxication. J Thorac Cardiovasc Surg. 2000; 120:424–425. [PubMed: 10917972]

28. Pasic M, Potapov E, Kuppe H, Hetzer R. Prolonged cardiopulmonary bypass for severe drug intoxication. *J Thorac Cardiovasc Surg.* 2000; 119:379–380. [PubMed: 10649215]
29. Hendren WG, Schieber RS, Garrettson LK. Extracorporeal bypass for the treatment of verapamil poisoning. *Ann Emerg Med.* 1989; 18:984–987. [PubMed: 2669572]

Figure 1.

Vital signs, venoarterial ECMO settings and vasopressor requirements during the patient's intensive care unit course. Vasopressor infusion rates were significantly reduced while maintaining a mean arterial pressure ≥ 60 mmHg after initiation of venoarterial ECMO. ECMO: extracorporeal membrane oxygenation.